SCHEMBL13005684

SCHEMBL13005684

CC(C)Cc1cccc(CN(CCN(C)C)Cc2cccc(F)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.53
CALM1 P0DP23 1/20 0.46
CAMKK2 Q96RR4 1/20 0.46
SLC6A3 Q01959 3/20 0.41
SLC6A2 P23975 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
RIPK1 Q13546 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
ROCK2 O75116 1/20 0.38
LIPE Q05469 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.37
ADRA2C P18825 1/20 0.36
HRH2 P25021 1/20 0.36
HTR2B P41595 1/20 0.36
SCD5 Q86SK9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005722 0.90 CALM1 (0.48) TAAR1CALM1CAMKK2MEN1KMT2A
SCHEMBL13005440 0.87 CALM1 (0.59) TAAR1CALM1CAMKK2SLC6A3SLC6A2
SCHEMBL13005625 0.85 BCHE (0.47) TAAR1CALM1CAMKK2SLC6A3SLC6A2
SCHEMBL13005633 0.85 CALM1 (0.40) TAAR1CALM1CAMKK2SLC6A3SLC6A2
SCHEMBL13005676 0.84 CALM1 (0.45) TAAR1CALM1CAMKK2SLC6A3SLC6A2
SCHEMBL13060692 0.84 TAAR1 (0.57) TAAR1CALM1CAMKK2SLC6A3MEN1
SCHEMBL13005692 0.83 TSHR (0.54) TAAR1CALM1CAMKK2RIPK1ALDH1A1
SCHEMBL13005702 0.83 TAAR1 (0.53) TAAR1CALM1CAMKK2MEN1KMT2A
SCHEMBL13005720 0.83 OPRK1 (0.49) CALM1CAMKK2MEN1KMT2AOPRM1
SCHEMBL13005575 0.83 CALM1 (0.41) TAAR1CALM1CAMKK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed